Teclistamab (i.v., 0.1-1 μg, once every 2 days) has anti-tumor activity at high doses in female NSG (NOD/SCID/γc / ) mice with H929 cells model[1].
| Animal Model: | Female NSG mice infected with H929 cell lines[1] |
| Dosage: | 0.1 μg (0.005 mg/kg), 0.5 μg (0.025 mg/kg), or 1 μg (0.05 mg/kg) |
| Administration: | i.v., on days 0, 3, 5, 7, and 10 |
| Result: | Completely inhibited tumor growth at doses of 0.5 and 1 μg, while no inhibition of tumor growth was observed at a dose of 0.1 μg. |
